[go: up one dir, main page]

TNSN99186A1 - Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques - Google Patents

Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques

Info

Publication number
TNSN99186A1
TNSN99186A1 TNTNSN99186A TNSN99186A TNSN99186A1 TN SN99186 A1 TNSN99186 A1 TN SN99186A1 TN TNSN99186 A TNTNSN99186 A TN TNSN99186A TN SN99186 A TNSN99186 A TN SN99186A TN SN99186 A1 TNSN99186 A1 TN SN99186A1
Authority
TN
Tunisia
Prior art keywords
prevention
carnitins
resveratrol
aging
producing
Prior art date
Application number
TNTNSN99186A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of TNSN99186A1 publication Critical patent/TNSN99186A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

-UN PRODUIT PHARMACEUTIQUE COMPORTANT SOUS FORME DE MELANGE OU SEPAREMENT J183CONDITIONNES : (A) L-CARNITINE OU UN ALKANOYL L-CARNITINE (TEL QUE L'ACETYL L-CARNITINE) ET (B) UN TRIHYDROXY OU TETRAHYDROXYSTILBENE (TEL QUE LE RESVERATROL), CONVENABLE POUR LA PREVENTION ET LE TRAITEMENT DES FORMES PATHOLOGIQUES DUS AUX TROUBLES NEURONAUX OU CEREBRAUX. I184
TNTNSN99186A 1998-10-09 1999-10-05 Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques TNSN99186A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998RM000636A IT1302365B1 (it) 1998-10-09 1998-10-09 Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali

Publications (1)

Publication Number Publication Date
TNSN99186A1 true TNSN99186A1 (fr) 2005-11-10

Family

ID=11406160

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99186A TNSN99186A1 (fr) 1998-10-09 1999-10-05 Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques

Country Status (27)

Country Link
US (1) US6515020B1 (fr)
EP (1) EP1117394B1 (fr)
JP (1) JP4166951B2 (fr)
KR (1) KR20010079981A (fr)
CN (1) CN1323205A (fr)
AR (1) AR020762A1 (fr)
AT (1) ATE249823T1 (fr)
AU (1) AU767492B2 (fr)
BR (1) BR9915918A (fr)
CA (1) CA2344893C (fr)
CZ (1) CZ2001920A3 (fr)
DE (1) DE69911441T2 (fr)
DK (1) DK1117394T3 (fr)
EE (1) EE200100205A (fr)
ES (1) ES2207287T3 (fr)
HK (1) HK1040935A1 (fr)
HU (1) HU229364B1 (fr)
IL (1) IL142046A0 (fr)
IS (1) IS5896A (fr)
IT (1) IT1302365B1 (fr)
NO (1) NO20011693L (fr)
PL (1) PL197342B1 (fr)
PT (1) PT1117394E (fr)
SK (1) SK3782001A3 (fr)
TN (1) TNSN99186A1 (fr)
TR (1) TR200100947T2 (fr)
WO (1) WO2000021526A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047193A (ja) * 2000-07-31 2002-02-12 Sunstar Inc アレルギー性皮膚炎予防または治療用組成物
WO2002038142A2 (fr) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions serotoninergiques et methodes de traitement de la deficience cognitive legere
BRPI0106382B1 (pt) * 2001-03-13 2017-07-11 Universidade Do Estado Do Rio De Janeiro - Uerj Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions
ATE342044T1 (de) * 2001-08-18 2006-11-15 Cognis Ip Man Gmbh Wirkstoffmischungen
US20070218151A1 (en) * 2002-03-12 2007-09-20 Universidade Do Estado Do Rio De Janeiro Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100574392B1 (ko) * 2003-02-07 2006-05-02 재단법인서울대학교산학협력재단 신경보호활성을 갖는 신규 페닐환 유도체 및 이를함유하는 약학 조성물
US20060084135A1 (en) 2003-07-01 2006-04-20 Howitz Konrad T Compositions for manipulating the lifespan and stress response of cells and organisms
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
KR100543056B1 (ko) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060121137A1 (en) * 2004-12-07 2006-06-08 Hartle Diane K Muscadine grape pomace in the treatment of intestinal inflammation
WO2006076681A2 (fr) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Compositions nouvelles pour le traitement des troubles de la neurodegenerescence et de la coagulation du sang
WO2006138418A2 (fr) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
EP2322158B1 (fr) 2005-10-26 2020-06-10 Kao Corporation Resveratrol et/ou extrait de grappes pour activier le metabolisme energetique
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
CA2676609A1 (fr) * 2007-01-26 2008-07-31 Washington University Methodes et compositions destinees au traitement de neuropathies
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
KR20130089158A (ko) * 2010-06-16 2013-08-09 시구마-토우인더스트리에파아마슈우티히리유니트에스.피이.에이. 신경 조직에서 신경발생을 증가시키기 위한 방법에 사용하기 위한 아세틸-카르니틴
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102919943A (zh) * 2012-10-26 2013-02-13 郑全辉 保健饮品-葡藤素
CN103877170B (zh) * 2012-12-19 2015-11-04 中国医学科学院药用植物研究所 一种虎杖的乙酸乙酯提取物及其制备方法和应用
CN119424497B (zh) * 2025-01-08 2025-06-24 万邦德制药集团有限公司 一种用于防治阿尔茨海默病、皮肤光老化的组合物、制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CH692837A5 (it) 1997-07-02 2002-11-29 Lisapharma Spa Composizione farmaceutica per uso alimentare, dietetico o medicinale adatta a migliorare l'assorbimento orale dei polifenoli e particolarmente del resveratrolo presenti nell'uva e nei suoi p
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase

Also Published As

Publication number Publication date
IS5896A (is) 2001-03-16
JP2002527389A (ja) 2002-08-27
DE69911441T2 (de) 2004-07-01
DK1117394T3 (da) 2004-01-26
IT1302365B1 (it) 2000-09-05
EP1117394B1 (fr) 2003-09-17
NO20011693D0 (no) 2001-04-04
HUP0104021A2 (hu) 2002-02-28
KR20010079981A (ko) 2001-08-22
HK1040935A1 (zh) 2002-06-28
CA2344893A1 (fr) 2000-04-20
AU767492B2 (en) 2003-11-13
PT1117394E (pt) 2004-02-27
HUP0104021A3 (en) 2003-12-29
IL142046A0 (en) 2002-03-10
ES2207287T3 (es) 2004-05-16
JP4166951B2 (ja) 2008-10-15
BR9915918A (pt) 2001-08-21
US6515020B1 (en) 2003-02-04
AU6121399A (en) 2000-05-01
ATE249823T1 (de) 2003-10-15
PL197342B1 (pl) 2008-03-31
TR200100947T2 (tr) 2001-07-23
PL347209A1 (en) 2002-03-25
CZ2001920A3 (cs) 2001-08-15
HU229364B1 (en) 2013-11-28
NO20011693L (no) 2001-04-04
EP1117394A1 (fr) 2001-07-25
DE69911441D1 (de) 2003-10-23
CA2344893C (fr) 2008-07-29
SK3782001A3 (en) 2001-10-08
AR020762A1 (es) 2002-05-29
ITRM980636A1 (it) 2000-04-10
CN1323205A (zh) 2001-11-21
EE200100205A (et) 2002-06-17
WO2000021526A1 (fr) 2000-04-20

Similar Documents

Publication Publication Date Title
TNSN99186A1 (fr) Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
FR2578421B1 (fr) Compositions pharmaceutiques utiles pour le traitement des troubles de la memoire
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
CA2199844A1 (fr) Composition pour le traitement d'affections de la peau
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2150184A1 (fr) Composition pharmaceutique pour le traitement des affections intestinales inflammatoires
EP0876149A4 (fr) Procede de traitement des troubles caracterises par une surexpression de la cytidine-desaminase ou de la desoxycytidine-desaminase
TW197423B (fr)
TNSN00106A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
CA2150183A1 (fr) Composition pharmaceutique pour le traitement des affections hemoroidales
FR2690854B1 (fr) Installation pour le traitement à très haute pression de produits liquides.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires
TNSN98123A1 (fr) Formes posologiques de sertraline et procede pour leur preparation
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
MA24682A1 (fr) Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
TNSN98193A1 (fr) Formes polymorphes de dofetilide, procede pour leur preparation et composition les contenant
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
KR880002535A (ko) 약제로서의 15-데옥시스퍼구알린의 용도
FR2575158B1 (fr) Arylalcoyloxymethyl-2 morpholines, leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central